RNAi

March 16, 2023 Alnylam's Paul Nioi, PhD on The Genetics Podcast: Using Genetics in Drug Target Discovery Paul Nioi, PhD, VP of Discovery and Translational Research and Head of Alnylam Human Genetics recently spoke with Dr. Patrick Short on The Genetics Podcast. Read More ›
September 10, 2020 Brendan Martin on the Pharmaphorum Podcast Alnylam’s Brendan Martin, Head of Europe, Middle East, Africa, and Canada and General Manager for the UK & Ireland, recently spoke on the Pharmaphorum podcast. Read More ›
May 1, 2020 John Maraganore on the "I Am BIO" Podcast: Destroying COVID's Genome Our CEO John Maraganore recently spoke with Biotechnology Innovation Organization (BIO) CEO and Chairman Jim Greenwood on the "I Am BIO" podcast. Read More ›
September 2, 2019 ORION-11: A Landmark Event for RNAi Therapeutics The results from the ORION-11 Phase 3 study of inclisiran, presented earlier today at the European Society of Cardiology meeting represent a landmark event... Read More ›
May 12, 2019 What is RNAi and How Do RNAi Therapeutics Work? What is RNAi? This video explains how Alnylam is leading the translation of RNAi to create an entirely new class of innovative medicines to treat disease. Read More ›
February 20, 2019 Alnylam Named a Fast Company World's Most Innovative Company for 2019 Alnylam has been named #3 in Biotech on Fast Company's World's 50 Most Innovative Company for 2019. Read More ›
January 3, 2019 John Maraganore Talks RNAi on Chemical & Engineering News Podcast John Maraganore talks with Chemical & Engineering News' Lisa Jarvis and Ryan Cross on this episode of C&EN's Stereo Chemistry podcast. Read More ›
May 9, 2018 First Rounders: John Maraganore Our CEO John Maraganore, Ph.D. recently chatted with the Nature Biotechnology Podcast about his path into science, through research and ultimately into biotech. Read More ›
Subscribe to RNAi